Aminoglycoside-resistance mechanisms were characterized in Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients during a recent clinical trial of inhaled tobramycin. Impermeability, in which bacteria have reduced susceptibility to all aminoglycosides, was the predominant mode of resistance in isolates obtained both before and after 6 months of cyclic treatment with tobramycin or placebo administered by aerosol. Enzymatic resistance mechanisms were found in fewer than 10% of resistant isolates. P. aeruginosa from individual patients could be grouped on the basis of genetic relatedness. When enzymatic resistance was involved, all isolates in a group had elevated tobramycin MICs. When impermeability occurred, MICs of a genotypic group varied from susceptible to resistant. These findings suggest that impermeability resistance occurs in only a fraction of the P. aeruginosa population in lungs of persons with CF and that this form of resistance arises by a process involving multiple small changes in MIC.
safety of long-term, intermittent aerosol administration of tobramycin (TOBI; PathoGenesis, Seattle) in treating CF patients with P. aeruginosa infections was recently completed [3] . This route of delivery yields high concentrations of the drug at the site of infection while minimizing systemic exposure and the consequent side effects of aminoglycosides. A modest decrease in tobramycin susceptibility of P. aeruginosa isolates was identified, but resistance mechanisms were not examined [4] . The objective of the current study was to determine the incidence of specific tobramycin-resistance mechanisms in P. aeruginosa isolated from patients prior to the trial and to determine whether this pattern was changed as a result of treatment.
Materials and Methods
Study design. The protocol for the inhaled tobramycin clinical trial has been described elsewhere [3] . Briefly, sputum or oropharyngeal samples were collected at regular visits over the 6-month trial period for quantitative microbiology. P. aeruginosa and other potential CF pathogens were identified by standard criteria [5] , and morphologically distinct isolates were saved from all patients at each sample collection. Antibiotic susceptibility testing was performed on all isolates, using a broth microdilution method [4] . This investigation focused on isolates from the 464 patients who completed 3 cycles of treatment and for whom complete microbiologic results were available.
To determine whether therapy had an effect on the incidence of a specific resistance mechanism, emphasis was placed on comparing isolates collected from patients in the placebo and tobramycin arms of the study. The first sample was collected at the visit immediately before the first therapy cycle and the second from the visit immediately after the end of the third cycle of therapy. Because multiple P. aeruginosa colony phenotypes are generally found on microbiologic plating of a CF sputum, 1 isolate of each phenotype was saved and tested for tobramycin susceptibility. For that time point, the isolate with the highest tobramycin MIC value was chosen to represent the population of bacteria from a patient, rather than that with the highest density, to maximize the number of drugresistant isolates studied. When an isolate had a tobramycin MIC у16 mg/mL, its mechanism of resistance was determined as described below. Molecular epidemiology. To understand more about the population of P. aeruginosa within individual CF patients, a more comprehensive series of isolates was studied. These isolates were collected at multiple points during the 6-month trial from 11 patients and were examined by randomly amplified polymorphic DNA (RAPD) polymerase chain reaction (PCR) to determine their genetic relatedness. The MICs of tobramycin-and aminoglycosideresistance mechanisms (in resistant isolates) were determined and correlated with RAPD PCR [6] .
Determination of tobramycin-resistance mechanisms. Three procedures were carried out on each resistant isolate, and the results were combined to ascertain the tobramycin-resistance mechanism. Isolates previously characterized as impermeability resistant or known to harbor aminoglycoside-resistance genes were used as positive controls in each of the assays.
The aminoglycoside-resistance profile (AGRP), which measured the susceptibility of each isolate to a panel of 12 aminoglycoside analogues, was done by use of the Kirby-Bauer disk diffusion assay [7] . Different inhibition patterns distinguished among the known enzymes that inactivate aminoglycosides by chemical modification.
When the susceptibility to all 12 aminoglycosides was decreased, something that no known enzyme is capable of, the resistance mechanism was operationally defined as "impermeability."
Southern hybridization was used to distinguish between overlapping AGRP patterns that occurred when multiple enzymes were present or when the presence of modifying enzymes was masked by high levels of impermeability. Southern analysis [1, 7] was performed with the following radiolabeled DNA probes:
ant(4 )-I, ant(4 )-II, aph(3 )-I, aph(3 )-II, aph(3 )-III, and aph(3 )-VI.
This method was limited to detecting genes for which probes were available, and it could not distinguish between functional and nonfunctional forms of a gene or between related but nonidentical genes.
The third procedure, PCR, was developed to permit sequencing of the modifying enzymes and to allow distinction between closely related genes that might give cross-hybridization on Southern analysis. PCR reactions were done under standard conditions [8] with primers designed to the following genes (GenBank accession no.):
and ant(4 )-IIa (M98270).
DNA RAPD PCR pattern. To determine whether P. aeruginosa isolates from individuals were genetically related, purified bacterial genomic DNA was subjected to RAPD PCR. The methodology and oligonucleotide primer D-10514 were used previously to compare P. aeruginosa isolates [6] . Bacteria were considered genotypically related if all the product bands were shared; differences in band intensity were not considered relevant. Isolate relationships were confirmed by a second primer: D-9891 or -1254 [6] .
Results
Tobramycin-resistance mechanisms. Of the 928 CF isolates of P. aeruginosa examined in this study, 143 (15.4%) had MICs у16 mg/mL and were drug resistant as defined by the National Committee for Clinical Laboratory Standards breakpoint for parenteral tobramycin therapy [9] . In all, 128 isolates (89.5%) lacked the aminoglycoside-modifying enzymes for which we tested and had reduced susceptibility for all aminoglycosides. These were classified as being resistant owing to impermeability (table 1). Eight isolates (5.6%) were identified as having only modifying enzymes for resistance, and 6 (4.2%) had both a modifying enzyme and impermeability. For 1 isolate, the resistance mechanism could not be determined.
In all cases in which AGRP identified AAC(6 )-II activity, PCR amplification occurred with the aac(6 )-Ib gene primers, but DNA sequencing of PCR products indicated the presence of an aac(6 )-Ib gene [10] . The encoded enzyme differs from AAC(6 )-Ib by a single amino acid, a change that converts its drug specificity to one identical to that of AAC(6 )-II. We believe that this is the first description of aac(6 )-Ib in P. aeruginosa. In general, the prevalence of each resistance mechanism was not noticeably changed by the 6 months of therapy, with impermeability the dominant mechanism (table 1) . Overall, the isolation of resistant P. aeruginosa increased in both the placebo and tobramycin groups, and the newly resistant isolates were of the impermeability type. Molecular epidemiology. For the 11 CF patients studied in detail, the majority of bacteria from each person fell into 1 or 2 unrelated P. aeruginosa genotypes (table 2). Other genotypes were only transiently detected. Two sibling patients (48-06 and 48-07) shared a genotype pattern.
Within each group of genotypically related isolates, there was a range of MICs (table 2) . In some cases all isolates were susceptible to tobramycin (e.g., genotype 4). When a modifying enzyme was present in a genotypic group, the majority of isolates, in general, were resistant (e.g., genotype 5). However, when impermeability was involved, the range of MICs was broader, and most isolates were susceptible (e.g., genotype 14).
A resistant isolate (MIC of tobramycin, у256 mg/mL) from patient 47-17 had the aac(6 )-Ib gene encoded on a 23-kb plasmid (data not shown). PCR analysis indicated that 15 of the 26 isolates collected from patient 47-17 had this gene. These same 15 isolates also fell into a single genotypic group (group 1). Therefore, the aminoglycoside-resistance gene and the plasmid were both found in a single genetically related subpopulation of bacteria, all of which had increased MICs of tobramycin. None of these features were found in the other P. aeruginosa isolates of patient 47-17.
Discussion
A recent clinical trial demonstrated the effectiveness of longterm inhaled tobramycin in treating P. aeruginosa lung infections of CF patients [3] . Over the 6-month therapy period, the majority of P. aeruginosa isolates from both the tobramycin and placebo arms of the study remained susceptible to tobramycin. However, in patients receiving inhaled tobramycin, a modest increase in tobramycin MIC 90 values was demonstrated [4] . The current study investigated the mechanisms of tobramycin resistance found in isolates from this trial.
We identified impermeability as the predominant aminoglycoside-resistance mechanism. Similar findings were reported elsewhere in smaller samples of the CF patient population [1, 2] . Although CF patients are treated with a variety of regimens for their disease, including intravenous tobramycin during acute exacerbation periods, comparison of isolates from the tobramycin and placebo arms gave no indication that the inhaled antibiotic therapy regimen changed the prevalence of aminoglycoside-resistance mechanisms. In particular, the presence of genes encoding drug-modifying enzymes that are often associated with transmissibility among organisms [11] and potentially among patients did not increase.
Miller et al. [12] examined aminoglycoside resistance in ∼2000 non-CF P. aeruginosa isolates and found a large diversity of resistance mechanisms. They noted the increasing emergence over time of isolates that were resistant to aminoglycosides by 11 mechanism (especially 2 different drug-modification enzymes). We observed no instances of CF isolates containing the genes for 2 different drug-modifying enzymes and only a few cases in which an enzymatic mechanism was combined with impermeability.
The molecular mechanism(s) determining impermeability resistance are not yet understood. Although ribosomes are the target of the aminoglycoside tobramycin, Hurley et al. [1] used cells permeabilized with ether to show that the ribosomes of P. aeruginosa isolates with impermeability resistance remained susceptible to aminoglycosides. Additional explanations for impermeability resistance include drug efflux pumps, new broadrange drug-modifying enzymes, and alterations in the lipopolysaccharide or outer-membrane proteins.
We observed that impermeability-resistant bacteria that were genotypically related and came from a single patient exhibited a wide range of tobramycin MICs. The MIC measurements were reproducible on retesting and were stable for single isolates grown in the absence of antibiotics through many generations. This suggests that high-level impermeability resistance develops starting with drug-susceptible backgrounds. We speculate that this occurs by a series of mutations, each causing a small change in the MIC. Because CF patients may be stably colonized by the same bacteria for long periods [13] , there is ample opportunity for such a multiple-step process to take place.
It is not clear why impermeability is the dominant resistance mechanism in CF P. aeruginosa isolates. Transfer of enzymatic resistance may be low because of a reduced frequency of conjugation or transformation, perhaps due to the microenvironment in the CF lung; the involvement of mucoid organisms [14] ; or the occurrence of these bacteria in biofilm microcolonies [15] . Alternatively, impermeability may give P. aeruginosa a selective advantage. This study provided examples of both enzymatic and impermeability mechanisms that result in high tobramycin MICs. However, there may be other phenotypic features that affect growth rate, expression of virulence factors, or interaction with the host immune system to give P. aeruginosa with impermeability resistance a competitive advantage.
In conclusion, impermeability resistance is the most frequent aminoglycoside-resistance mechanism found in CF patients. This was unaltered by 6 months of cyclic inhaled tobramycin therapy. Studies are under way to determine how impermeability resistance occurs and whether it involves a single mechanism or many.
